Trial
NCT04347226
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Columbia University
Collaborators
Bristol-Myers Squibb
Condition
Solid Tumor
Intervention
BMS-986253
Why stopped
Interim analysis indicated that futility boundary was reached.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-22